[1] GINèS P,GUEVARA M. Hyponatremia in cirrhosis：pathogenesis,clinical significance,and management[J]. Hepatology,2008,48（3）：1002-1010.
[2] HEUMAN DM,ABOU-ASSI SG,HABIB A,et al. Persistent ascites and low serum sodium identify patients with cirrhosis and low MELD scores who are at high risk for early death[J]. Hepatology,2004,40（4）：802-810.
[3] 刘建军,智红,王文新,等. 肝硬化腹水限钠治疗利弊关系的商榷. 河北医药,1999,21（1）：13-14.
[4] LISA M,FORMAN M,MICHAEL R,et al. Predicting the prognosis of chronic liver disease：An evolution from Child to MELD[J]. Hepatology,2001,33：473-475.
[5] RUF AE,KREMERS WK,CHAVEZ LL,et al. Addition of serum sodium into the MELD score predicts waiting list mortality better than MELD alone[J]. Liver Transplant,2005,11：336-343.
[6] BORRONI G,MAGGO A,SANGIOYANNI A,et al. Clinical revelance of hyponatremia for the hospital outcome of cirrhotic patient[J]. Dig Liver Dis,2000,32：605-610.
[7] MALINCHOC M,KAMATH PS,GOTDON FD,et al. A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunt[J]. Hepatology,2000,31：864-871.
[8] 曹建国,邓玉花,彭吉芳. 失代偿期肝硬化患者并发低钠血症172例临床分析[J]. 实用肝脏病杂志,2006,9（6）：369-370. |
